Befovacimab PK and TFPI target binding
A QSS-TMDD model representing intravenous or subcutaneous befovacimab disposition, TFPI turnover, free antibody, and antibody–TFPI complex dynamics.
- Therapeutic
- Befovacimab, BAY 1093884 / befovacimab
- Target
- TFPI, tissue factor pathway inhibitor
- Disease
- Ocular disease
Biological model
A QSS-TMDD model representing intravenous or subcutaneous befovacimab disposition, TFPI turnover, free antibody, and antibody–TFPI complex dynamics.
Model details
A QSS-TMDD model representing intravenous or subcutaneous befovacimab disposition, TFPI turnover, free antibody, and antibody–TFPI complex dynamics.
Modeled states
- auc mg h Lmg*h/L
Modeled dynamic state for auc mg h l.
- central total nmol kgnmol/kg
Modeled dynamic state for central total nmol kg.
- elapsed hh
Modeled dynamic state for elapsed h.
- peripheral free nmol kgnmol/kg
Modeled dynamic state for peripheral free nmol kg.
- sc fast depot nmol kgnmol/kg
Modeled dynamic state for sc fast depot nmol kg.
- sc slow depot nmol kgnmol/kg
Modeled dynamic state for sc slow depot nmol kg.
- sc slow transit nmol kgnmol/kg
Modeled dynamic state for sc slow transit nmol kg.
- target total nMnM
Modeled dynamic state for target total nm.
Key readouts
- Total central befovacimabunknown
Model-derived readout for total central befovacimab.
- Free central befovacimabunknown
Model-derived readout for free central befovacimab.
- Total TFPInM
Model-derived readout for total tfpi.
- Befovacimab–TFPI complexunknown
Model-derived readout for befovacimab–tfpi complex.
- Cumulative exposuremg*h/L
Model-derived readout for cumulative exposure.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
cynomolgus IV 5 mg/kg QSS-TMDD
How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex? Explore this biological starting configuration through Total central befovacimab, Free central befovacimab, Total TFPI, Befovacimab–TFPI complex, Cumulative exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?
cl L h kg
Model parameter controlling cl l h kg.
Exploratory range around the default value.
5 evenly spaced values in L/h/kg. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
